Company intelligence / Profile preview

Hualu Group

Jinan, Shandong, Chinahl-hengsheng.com ↗

Ownership: Private
Development stage: Other

Overview

Hualu Holdings is a large Chinese state-owned conglomerate with business interests spanning chemicals, energy, and pharmaceuticals. Its pharmaceutical arm, Xinhua Pharmaceutical, is a major producer of generic drugs such as ibuprofen tablets. In December 2024, nearly 360,000 boxes of ibuprofen produced by Xinhua Pharmaceutical were exported to New Zealand as OTC products—marking a significant milestone in entering the retail market in Oceania[1]. The group's main focus remains on industrial chemicals and manufacturing.

Modalities: Small molecule
Industry: Chemicals & Materials

Beyond the preview

Go deeper on Hualu Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hualu Group.

Explore the full profile